PRONIRAS - Key Persons

Job Titles:

• Member of the Management Team

Dr. Toombs serves as co-Founder and Chief Scientific Officer for Proniras Corporation. At Proniras, Dr. Toombs is responsible for overseeingthe tezampanel development program. Prior to his role at Proniras, Dr. Toombs was also a co-founder and Chief Scientific Officer of Faraday Pharmaceuticals beginning in 2014. Prior to Faraday, Dr. Toombs served as Senior Director Preclinical Development at Ikaria from 2006-2011 where he was responsible for the IND enabling studies and the commencement of the first in human study of IK-1001. Before Ikaria, Dr. Toombs served in increasing roles and responsibilities in research and product development at Amgen from 1994-2006 and arrived in the Seattle area following the Amgen acquisition of Immunex in 2002. Dr. Toombs graduated from Wheaton College with a BS in Biology and continued on to earn a PhD in Physiology-Pharmacology from the Bowman Gray School of Medicine at Wake Forest University. He completed a postdoctoral tenure at Upjohn Laboratories and is a current Diplomate of the American Board of Toxicology.

Job Titles:

• Member of the Management Team
• Vice President of Finance

Ms. Lindsay Rayle serves as Vice President of Finance for Proniras Corporation. At Proniras, Ms. Rayle oversees all finance, accounting and day-to-day internal operations for the Company. Ms. Rayle has more than 20 years of tax, accounting, finance, and operations management experience. Prior to her role at Proniras, Ms. Rayle served in various senior-level finance and operating roles at Accelerator Corporation, a leading life science investment and management firm. Prior to her role at Accelerator, Ms. Rayle held a variety of finance and accounting positions at Prolinx, Inc., a private, venture-backed company that developed, manufactured, and marketed chemistry based tools, applications, and systems to advance drug discovery. Before joining Prolinx, Ms. Rayle worked as a Trust Associate for Plan Member Services Corporation. Ms. Rayle received an MBA from Seattle University and a BA in Business Administration with an emphasis in Accounting from the University of Puget Sound.

Job Titles:

• Member of the Board of Directors
• Managing Director at ARCH Venture Partners

Steven Gillis is now a Managing Director at ARCH Venture Partners. Dr. Gillis was a founder and director of Corixa Corporation and served as the company's Chief Executive Officer since inception and as its chairman since January of 1999. Corixa Corporation was acquired by GlaxoSmithKline in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex's Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex's Research and Development subsidiary. Dr. Gillis was interim Chief Executive officer of Immunex Corporation following its majority purchase by American Cyanamid Company. Dr. Gillis remained on the Board of Directors of Immunex until 1997. Immunex was acquired by Amgen in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978.

Job Titles:

• Chief Executive Officer
• Member of the Board of Directors
• President
• President and Chief Executive Officer ( CEO ) of Accelerator Life Science Partners

Thong Q. Le serves as President and Chief Executive Officer (CEO) of Accelerator Life Science Partners. With more than 20 years of experience in identifying, investing, managing, and successfully exiting numerous seed and early-stage investments, Mr. Le is positioned to grow and expand the Accelerator investment model. He currently serves as CEO and Director of all Accelerator Life Science Partner I portfolio companies, which currently includes ApoGen Biotechnologies, Lodo Therapeutics, Proniras Corporation, and Rodeo Therapeutics. He also serves as a director of Acylin Therapeutics, AgTech Accelerator, and Petra Pharma. Prior to becoming CEO at Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation in Seattle, WA. During his 13-year tenure at WRF Capital, Mr. Le played a significant role in the early sourcing, financing, and development of numerous start-up companies, including Alder Biopharmaceuticals (NASDAQ: ALDR), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO.L), Hyperion Therapeutics (Nasdaq: HPTX), Lumera (Nasdaq NM: LMRA), Performant (acquired by Mercury Interactive), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). He also led WRF Capital's investments in Accelerator, AnswerDash, ARZEDA, Cardeas Pharma, Resolve Therapeutics, and Uptake Medical, all companies where he was actively involved in establishing as a founding or early investor. Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures. Mr. Le completed post-graduate studies at the Templeton College of Oxford University and earned a bachelor of arts cum laude in government from Harvard University. He currently serves on the advisory board for the Alexandria Seed Capital Platform and on the executive committees of the Evergreen Venture Capital Association (EVCA) and Washington Global Health Fund. He was previously named one of the region's "40 Under 40" by the Puget Sound Business Journal.